Hoffman ALS Clinical Trial Awards Recipients
There is an urgent need for new and improved therapies for ALS. To help accelerate their development, we are proud to support early-stage clinical trials like these through our Hoffman ALS Clinical Trial Awards Program.
2024 Recipient
William Clementi, Ph.D., Tiziana Life Sciences Ltd.
Modulation of ALS Neuroinflammation by Nasal anti-CD3 Monoclonal Antibody
LEARN MORE ABOUT OUR 2024 RECIPIENT
2023 Recipients
Swathy Chandrashekhar, M.D., University of Kansas Medical Center Research Institute
Ranolazine in ALS: Safety and Effect on Cramps, Function and Quality of Life
Erin Fleming, ProJenX
A Phase 1c Study of Prosetin, a Brain-Penetrant MAP4Ki, in People with ALS
Pierre Miniou, Ph.D., InFlectis BioScience
Pharmacodynamic Biomarkers Evaluation in Phase 2 Trial in Bulbar-Onset ALS
Irving Sucholeiki, Ph.D., Aquilus Pharmaceuticals
Clinical Trial of a Matrix Metalloproteinase Inhibitor for the Treatment of ALS
LEARN MORE ABOUT OUR 2023 RECIPIENTS
2022 Recipient
Laura Ranum, Ph.D., University of Florida
Safety and Therapeutic Potential of Metformin for C9orf72 ALS
LEARN MORE ABOUT OUR 2022 RECIPIENT
2021 Recipients
Daniel Fowler, M.D., Rapa Therapeutics
RAPA-501 Hybrid TREG/Th2 Cell Therapy of ALS
Eran Hornstein, M.D., Ph.D., Weizmann Institute of Science, Israel
Repurposing Enoxacin Therapy for Patients with ALS
Richard Robitaille, Ph.D., University of Montreal, Canada
Target NMJ to Maintain Motor Functions in ALS
Barbara Smith, Ph.D., University of Florida
Acute Adenosine Receptor Antagonism to Promote Breathing Plasticity in ALS
